Nonacog beta pegol
Refixia (nonacog beta pegol) is a protein pharmaceutical. Nonacog beta pegol was first approved as Refixia on 2017-06-02. It has been approved in Europe to treat hemophilia b.
| Trade Name | Refixia |
|---|---|
| Common Name | Nonacog beta pegol |
| Indication | hemophilia b |
| Drug Class | Pegylated compounds |
